JPWO2019213005A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019213005A5 JPWO2019213005A5 JP2020560316A JP2020560316A JPWO2019213005A5 JP WO2019213005 A5 JPWO2019213005 A5 JP WO2019213005A5 JP 2020560316 A JP2020560316 A JP 2020560316A JP 2020560316 A JP2020560316 A JP 2020560316A JP WO2019213005 A5 JPWO2019213005 A5 JP WO2019213005A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- compound according
- formula
- pharmaceutically acceptable
- independently selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 21
- 125000000217 alkyl group Chemical group 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 9
- 125000000623 heterocyclic group Chemical group 0.000 claims 8
- -1 2-hydroxyphenyl Chemical group 0.000 claims 7
- 125000004452 carbocyclyl group Chemical group 0.000 claims 7
- 125000005843 halogen group Chemical group 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 229910052799 carbon Inorganic materials 0.000 claims 6
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 125000005647 linker group Chemical group 0.000 claims 4
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 3
- 239000003446 ligand Substances 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 230000008685 targeting Effects 0.000 claims 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 125000005549 heteroarylene group Chemical group 0.000 claims 2
- 125000004043 oxo group Chemical group O=* 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 claims 1
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 claims 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 229910052805 deuterium Inorganic materials 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 125000003827 glycol group Chemical group 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024004034A JP2024041923A (ja) | 2018-04-30 | 2024-01-15 | Ｐｏｌｙｂｒｏｍｏ－１（ｐｂｒｍ１）の小分子分解剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862664592P | 2018-04-30 | 2018-04-30 | |
| US62/664,592 | 2018-04-30 | ||
| PCT/US2019/029778 WO2019213005A1 (en) | 2018-04-30 | 2019-04-30 | Small molecule degraders of polybromo-1 (pbrm1) |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024004034A Division JP2024041923A (ja) | 2018-04-30 | 2024-01-15 | Ｐｏｌｙｂｒｏｍｏ－１（ｐｂｒｍ１）の小分子分解剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021522276A JP2021522276A (ja) | 2021-08-30 |
| JPWO2019213005A5 true JPWO2019213005A5 (de) | 2022-05-09 |
| JP7471232B2 JP7471232B2 (ja) | 2024-04-19 |
Family
ID=68386081
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020560316A Active JP7471232B2 (ja) | 2018-04-30 | 2019-04-30 | Ｐｏｌｙｂｒｏｍｏ－１（ｐｂｒｍ１）の小分子分解剤 |
| JP2024004034A Pending JP2024041923A (ja) | 2018-04-30 | 2024-01-15 | Ｐｏｌｙｂｒｏｍｏ－１（ｐｂｒｍ１）の小分子分解剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024004034A Pending JP2024041923A (ja) | 2018-04-30 | 2024-01-15 | Ｐｏｌｙｂｒｏｍｏ－１（ｐｂｒｍ１）の小分子分解剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11771697B2 (de) |
| EP (1) | EP3787747A4 (de) |
| JP (2) | JP7471232B2 (de) |
| AU (1) | AU2019261938B2 (de) |
| CA (1) | CA3093405A1 (de) |
| WO (1) | WO2019213005A1 (de) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018237026A1 (en) | 2017-06-20 | 2018-12-27 | C4 Therapeutics, Inc. | N / O-LINKED DEGRONS AND DEGRONIMERS FOR DEGRADATION OF PROTEINS |
| EP3710002A4 (de) | 2017-11-16 | 2021-07-07 | C4 Therapeutics, Inc. | Degrader und degrone für gezielten proteinabbau |
| JP2021519337A (ja) | 2018-03-26 | 2021-08-10 | シー４ セラピューティクス， インコーポレイテッド | Ｉｋａｒｏｓの分解のためのセレブロン結合剤 |
| EP3781156A4 (de) | 2018-04-16 | 2022-05-18 | C4 Therapeutics, Inc. | Spirocyclische verbindungen |
| EP3784665A4 (de) * | 2018-04-26 | 2022-01-26 | Aurigene Discovery Technologies Limited | Pyridazinderivate als smarca2/4-abbauer |
| CN114599428A (zh) * | 2019-10-28 | 2022-06-07 | 豪夫迈·罗氏有限公司 | 双功能化合物 |
| CN114728936A (zh) * | 2019-10-29 | 2022-07-08 | 豪夫迈·罗氏有限公司 | 用于治疗癌症的双功能化合物 |
| BR112022012410A2 (pt) | 2019-12-23 | 2022-08-30 | Kymera Therapeutics Inc | Degradadores smarca e usos dos mesmos |
| MX2022008487A (es) * | 2020-01-10 | 2022-08-02 | Amgen Inc | Degradadores de smarca2-vhl. |
| AU2021320155A1 (en) * | 2020-08-07 | 2023-02-09 | Cornell University | Therapeutic cure-pro compounds for targeted degradation of bet domain proteins, and methods of making and using them |
| CA3199652A1 (en) * | 2020-11-20 | 2022-05-27 | Matthew Netherton | Compounds and uses thereof |
| EP4384517A1 (de) | 2021-08-09 | 2024-06-19 | Genentech, Inc. | Phenolderivate zur verwendung bei der modulation von brm |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9694084B2 (en) | 2014-12-23 | 2017-07-04 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| MA41598A (fr) * | 2015-02-25 | 2018-01-02 | Constellation Pharmaceuticals Inc | Composés thérapeutiques de pyridazine et leurs utilisations |
| WO2017030814A1 (en) | 2015-08-19 | 2017-02-23 | Arvinas, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| SG11201808728QA (en) * | 2016-04-06 | 2018-11-29 | Univ Michigan Regents | Mdm2 protein degraders |
| EP3455219A4 (de) * | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | Amingebundene c3-glutarimiddegronimere für zielproteinabbau |
| WO2018052949A1 (en) * | 2016-09-13 | 2018-03-22 | The Regents Of The University Of Michigan | Fused 1,4-diazepines as bet protein degraders |
| WO2019023149A1 (en) | 2017-07-24 | 2019-01-31 | Salk Institute For Biological Studies | USE OF BROMODOMAIN-CONTAINING PROTEIN-9 ANTAGONISTS IN ASSOCIATION WITH VITAMIN D RECEPTOR AGONISTS IN THE TREATMENT OF DIABETES |
| EP3774789A1 (de) * | 2018-04-01 | 2021-02-17 | Arvinas Operations, Inc. | Auf brm abzielende verbindungen und zugehörige verfahren zur verwendung |
| EP3784665A4 (de) * | 2018-04-26 | 2022-01-26 | Aurigene Discovery Technologies Limited | Pyridazinderivate als smarca2/4-abbauer |
-
2019
- 2019-04-30 WO PCT/US2019/029778 patent/WO2019213005A1/en unknown
- 2019-04-30 AU AU2019261938A patent/AU2019261938B2/en active Active
- 2019-04-30 EP EP19797003.1A patent/EP3787747A4/de active Pending
- 2019-04-30 CA CA3093405A patent/CA3093405A1/en active Pending
- 2019-04-30 JP JP2020560316A patent/JP7471232B2/ja active Active
- 2019-04-30 US US17/042,634 patent/US11771697B2/en active Active
-
2024
- 2024-01-15 JP JP2024004034A patent/JP2024041923A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2019213005A5 (de) | ||
| JP2020520926A5 (de) | ||
| JPWO2019165229A5 (de) | ||
| RU2020123241A (ru) | Полициклические соединения в качестве аллостерических ингибиторов shp2 | |
| JP2019535744A5 (de) | ||
| CA2651375C (en) | Treatment of cell proliferative disorders | |
| JPWO2020033828A5 (de) | ||
| JP2019535746A5 (de) | ||
| RU2016142704A (ru) | Замещенные-6,8-диоксабицикло[3.2.1.]октан-2,3-диольные соединения в качестве агентов, нацеленных на ASGPR | |
| JP2018516243A5 (de) | ||
| JP2018511628A5 (de) | ||
| JP2010506854A5 (de) | ||
| JP2021063058A5 (de) | ||
| WO2023131219A1 (en) | Conjugates, compositions and methods of use | |
| Xiao et al. | Design, synthesis and biological evaluation of the thioether-containing lenalidomide analogs with anti-proliferative activities | |
| JPWO2019031614A5 (de) | ||
| JP2010520269A (ja) | カンナビノイドの新規キノノイド誘導体及び悪性腫瘍の治療におけるそれらの使用 | |
| JP2020532562A (ja) | 生物学的製剤の粘度を低下させるための化合物 | |
| JPWO2019213445A5 (de) | ||
| DK2882708T3 (en) | NEW CONNECTIONS AND APPLICATIONS THEREOF | |
| KR20200070254A (ko) | 면역접합체에서 메티오닌 산화를 방지하는 방법 | |
| JPWO2020102096A5 (de) | ||
| CA3028122A1 (en) | Porphyrin compounds and compositions useful for treating cancer | |
| WO2020166592A1 (ja) | ヘミアスタリン誘導体とその抗体薬物複合体 | |
| JP2018123122A (ja) | カリケアマイシン誘導体およびその抗体薬物コンジュゲート |